Press release

Pat Growth 25pctExceptional ItemResults View source PDF Explain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹780.00

prior close

₹801.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%-0.4% vs market

Pharmaceuticals & Biotechnology peers, median of 162sector · industry level+0.3%-0.4% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+1.0

15m

+0.8

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1+0.4-0.4+0.3-0.4

Next day

-1.3+0.5-1.8+0.7-2.0

-0.5+0.6-1.1+0.4-1.0

-2.2+1.4-3.7+1.7-3.9

-1.3+1.9-3.1+1.8-3.1

-3.0+2.3-5.3+2.0-5.0

-3.8-0.5-3.4+1.3-5.1

15d

+0.0-2.9+2.9-0.6+0.6

-1.7+3.1-4.8+3.8-5.4

+1.2+3.2-2.0+7.8-6.6

+12.2+4.5+7.6+8.2+3.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anthem Biosciences reported strong FY26 results with consolidated revenue from operations at ₹21,243 Mn (up 15.2% YoY). EBITDA grew 30.8% to ₹9,896 Mn with 43.4% margins, while PAT jumped 31.1% to ₹5,918 Mn at 26.0% margins. Q4FY26 was the best quarter ever with revenue of ₹6,109 Mn (+26.4% YoY), EBITDA of ₹3,184 Mn at 48.1% margins, and PAT of ₹1,898 Mn, a near doubling from Q4FY25. The company flagged an exceptional item of ₹244 Mn net expense related to new Indian labour codes, partially reversed by a ₹10 Mn credit in Q4. Other income surged 81.8% to ₹1,558 Mn, driven by higher forex gains and RoDTEP incentives. Net cash position stands at ₹13,743 Mn.

Likely market impact

Anthem delivered robust double-digit growth across revenue, EBITDA and PAT in FY26, with Q4 showing exceptional acceleration. PAT growth of 31.1% and EBITDA growth of 30.8% signal strong operational leverage despite margin compression at the full-year level. The ₹244 Mn exceptional labour code charge is a one-time item unlikely to materially impact the stock's positive trajectory.